Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 April 2020Big PharmaRory O'Neill

Gilead told to waive remdesivir patent rights

Almost 150 health and poverty activist campaigns, including  Médecins Sans Frontières, have urged  Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Americas
US govt doesn’t have remdesivir patent rights, says GAO
1 April 2021   The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Americas
US govt doesn’t have remdesivir patent rights, says GAO
1 April 2021   The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.

More on this story

Generics
Gilead agrees 127-country remdesivir licence with generic makers
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Americas
US govt doesn’t have remdesivir patent rights, says GAO
1 April 2021   The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility